Related Experiment Video

Updated: May 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Treating HCV in HIV 2013: on the cusp of change

Valérie Martel-Laferrière1, Douglas T Dieterich

  • 1Département de Microbiologie et Infectiologie, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.

Liver International : Official Journal of the International Association for the Study of the Liver
|December 31, 2013
PubMed

Insights

Treating co-infected HIV/HCV patients with direct-acting antiviral agents (DAAs) shows promise. This review examines current data and challenges for DAAs in treating hepatitis C virus (HCV) among these patients.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) treatment in HIV/HCV co-infected patients presents unique challenges.
  • Traditional treatments like pegylated-interferon and ribavirin yield disappointing sustained virological response rates in this population.
  • Direct-acting antiviral agents (DAAs) have revolutionized HCV treatment in mono-infected patients.

Purpose of the Study:

  • To review available data on the efficacy and safety of DAAs in HIV/HCV co-infected patients.
  • To identify and discuss the challenges associated with using DAAs in this specific patient group.
  • To provide an overview of ongoing research and future directions for HCV treatment in co-infected individuals.

Main Methods:

  • Literature review of clinical trials and observational studies.
  • Analysis of data on DAA efficacy, safety, and drug interactions in HIV/HCV co-infected patients.
  • Synthesis of information regarding treatment challenges and ongoing research.

Main Results:

  • While no DAAs are specifically approved for co-infected patients, numerous studies are underway.
  • Emerging data suggest potential benefits of DAAs in achieving sustained virological response in this population.
  • Challenges include potential drug-drug interactions and the need for optimized treatment regimens.

Conclusions:

  • DAAs represent a promising therapeutic advancement for HIV/HCV co-infected patients.
  • Further research and specific clinical guidelines are needed to optimize DAA use in this population.
  • Addressing treatment challenges is crucial for improving outcomes in co-infected individuals.

Keywords:
HIVco-infectiondirect acting antiviral agentshepatitis C

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K